HES6 and prostate cancer: To test the functional relevance of HES6 in the transition to CRPC, we stably overexpressed HA-tagged HES6 in androgen-sensitive prostate cancer LNCaP and DuCaP cells, which induced reduced sensitivity to bicalutamide (Supplementary Fig S2B–D).